Sei Investments Co. Makes New $295,000 Investment in AngioDynamics, Inc. $ANGO

Key Points

• Sei Investments Co. has acquired a new position in AngioDynamics, purchasing 31,500 shares valued at approximately $295,000, marking their ownership at 0.08% of the company.
• AngioDynamics recently reported quarterly earnings, surpassing expectations with revenue of $80.16 million and earnings per share of ($0.03), indicating a 13.0% increase in revenue year-over-year.
• Several institutional investors have significantly increased their stakes in AngioDynamics, with notable changes including a 667.0% stake increase by the New York State Common Retirement Fund during the first quarter.

Sei Investments Co. bought a new stake in AngioDynamics, Inc. (NASDAQ:ANGO - Free Report) in the first quarter, according to its most recent filing with the Securities & Exchange Commission. The firm bought 31,500 shares of the medical instruments supplier's stock, valued at approximately $295,000. Sei Investments Co. owned 0.08% of AngioDynamics at the end of the most recent quarter.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Squarepoint Ops LLC purchased a new stake in shares of AngioDynamics in the 4th quarter valued at about $387,000. Ameriprise Financial Inc. increased its position in AngioDynamics by 24.0% in the 4th quarter. Ameriprise Financial Inc. now owns 277,565 shares of the medical instruments supplier's stock valued at $2,542,000 after acquiring an additional 53,675 shares during the period. GAMMA Investing LLC increased its position in AngioDynamics by 1,281.4% in the 1st quarter. GAMMA Investing LLC now owns 13,897 shares of the medical instruments supplier's stock valued at $130,000 after acquiring an additional 12,891 shares during the period. GSA Capital Partners LLP acquired a new position in AngioDynamics in the 1st quarter valued at about $642,000. Finally, New York State Common Retirement Fund increased its position in AngioDynamics by 667.0% in the 1st quarter. New York State Common Retirement Fund now owns 54,635 shares of the medical instruments supplier's stock valued at $513,000 after acquiring an additional 47,512 shares during the period. 89.43% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

ANGO has been the topic of several recent analyst reports. Canaccord Genuity Group boosted their target price on AngioDynamics from $15.00 to $17.00 and gave the stock a "buy" rating in a research report on Wednesday, July 16th. Wall Street Zen upgraded AngioDynamics from a "hold" rating to a "buy" rating in a research report on Saturday, August 16th. HC Wainwright reiterated a "buy" rating and set a $16.00 target price on shares of AngioDynamics in a research report on Wednesday, July 16th. Finally, Lake Street Capital initiated coverage on AngioDynamics in a report on Wednesday, July 16th. They issued a "buy" rating and a $24.00 price target on the stock. Three investment analysts have rated the stock with a Buy rating, According to MarketBeat, the company presently has a consensus rating of "Buy" and a consensus target price of $19.00.

AngioDynamics Stock Performance

ANGO stock traded up $0.01 on Thursday, reaching $9.14. The company had a trading volume of 97,986 shares, compared to its average volume of 628,651. AngioDynamics, Inc. has a 1 year low of $5.83 and a 1 year high of $13.50. The company's fifty day moving average is $9.31 and its 200 day moving average is $9.62. The company has a market cap of $371.36 million, a P/E ratio of -11.01 and a beta of 0.67.

AngioDynamics (NASDAQ:ANGO - Get Free Report) last posted its earnings results on Tuesday, July 15th. The medical instruments supplier reported ($0.03) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.12) by $0.09. AngioDynamics had a negative return on equity of 3.20% and a negative net margin of 11.62%.The firm had revenue of $80.16 million for the quarter, compared to analyst estimates of $74.26 million. During the same quarter in the prior year, the company earned ($0.06) EPS. AngioDynamics's revenue was up 13.0% on a year-over-year basis. AngioDynamics has set its FY 2026 guidance at -0.350--0.250 EPS. On average, sell-side analysts predict that AngioDynamics, Inc. will post -0.37 earnings per share for the current year.

About AngioDynamics

AngioDynamics, Inc, a medical technology company, engages in the design, manufacture, and sale of medical, surgical, and diagnostic devices for the use in treating peripheral vascular disease, and oncology and surgical settings in the United States and internationally. The company offers Auryon Atherectomy system that is designed to deliver an optimized wavelength, pulse width, and amplitude to remove lesions while preserving vessel wall endothelium.